Category Archives: Psoriasis

Aim Ayurveda by Dr Rakesh Aggarwal interview on Arthritis
Aim Ayurveda founded by Dr. Rakesh Aggarwal is a super specialty center for Chronic Diseases. Dr. Aggarwal is having an experience of 18 long years with an excellent track record, especially in the treatment for chronic disorders like; bull; Arthritis (Joint Pains:- Rheumatoid Arthritis, Gout, Osteo Arthritis, Cervical Spondylosis etc.) bull; Hepatitis- B C and Cirrhosis of Liver bull; Kidney Failure and Kidney Stones bull; Skin problems,( Psoriasis, Eczema etc.)From:aim ayurvedaViews:8 0ratingsTime:09:56More inPeople Blogs

Excerpt from:
Aim Ayurveda by Dr Rakesh Aggarwal interview on Arthritis - Video

Fitzpatricks Dermatology in
Buy from Amazon CA Site http://www.amazon.ca Product Description Fitzpatricks Dermatology in The landmark dermatology text that bridges the gap between science and clinical medicine mdash;updated for today #39;s practice Generations of clinicians, skin biologists, residents, and educators have acclaimed Fitzpatrick #39;s as the most authoritative and complete guide to dermatologic basic sciences, histopathology, diagnosis, and treatment. Edition after edition, it reflects the latest insights into skin diseases and skin biology mdash;and their practical relevance to general internal medicine mdash;while covering the scientific foundations of the specialty. This classic yet cutting-edge text is supported by the expert insights of more than 500 internationally respected contributors, and it covers everything dermatologists need to know about skin, dermatologic signs of underlying disease, and the management of all skin diseases, including acne, skin cancer, and psoriasis. FEATURES More than 3000 full-color photographs DVD with image bank includes downloadable figures from the text New illustration style makes difficult concepts easier to understand Therapeutic ladders with first, second, and third line therapies New or thoroughly revised chapters onPsoriasis;Skin disease in immunosuppressed patients;Epidermal stem cells;Hair growth disorders;Neonatal, pediatric, and adolescent dermatology;Radiotherapy;Immunobiologicals and cytokines;Lasers for rejuvenation Expanded medical and surgical therapeutics sections ...From:Katerine LeroyViews:0 0ratingsTime:00:40More inScience Technology

Original post:
Fitzpatricks Dermatology in - Video

Drug Discovery and
Buy from Amazon CA Site http://www.amazon.ca Product Description Drug Discovery and This two volume set provides a comprehensive account of the entire sequence of operations involved in discovering a drug through the actual delivery of the drug to clinicians and medical practitioners. Includes case studies of the discovery of erythromycin analogs (antibiotics), Tagamet, and Ultiva (remifentanil)Discusses the discovery of agents for the treatment and management of bacterial infections, Parkinson #39;s disease, psoriasis, ulcers and stomach pain, atopic dermatitis, asthma, and cancerContains chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomicsThe first volume of this set thoroughly describes conceptualizing a drug, creating a library of candidates for testing, screening those candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and revising the drug as necessary. Disclaimer: Orchid is a participant in the Amazon.ca, Inc. Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon CA Site. Amazon and the Amazon logo are trademarks of Amazon, Inc. or its affiliates.From:Roberto ColburnViews:0 0ratingsTime:00:40More inGaming

Read the original here:
Drug Discovery and - Video

Carboxytherapy gun MESALYSE (psoriasis)
Carboxytherapy MESALYSE -- CO #8322; reduces changes in psoriasis. Treatment is completely safe, made without anesthesia, quick and extremely effective. http://www.esteticline.plFrom:esteticlineszczecinViews:0 0ratingsTime:00:19More inEducation

Continued here:
Carboxytherapy gun MESALYSE (psoriasis) - Video

aim ayurveda(Dr Rakesh Aggarwal)
Aim Ayurveda founded by Dr. Rakesh Aggarwal is a super specialty center for Chronic Diseases. Dr. Aggarwal is having an experience of 18 long years with an excellent track record, especially in the treatment for chronic disorders like; 1. Arthritis (Joint Pains:- Rheumatoid Arthritis, Gout, Osteo Arthritis, Cervical Spondylosis etc.) 2. Hepatitis- B C and Cirrhosis of Liver 3. Kidney Failure and Kidney Stones 4. Skin problems,( Psoriasis, Eczema etc)From:aim ayurvedaViews:10 1ratingsTime:09:51More inPeople Blogs

View original post here:
aim ayurveda(Dr Rakesh Aggarwal) - Video

Blasting for Skin Disorders
Skin disorders, like eczema, psoriasis, and others, are often worsened by eating the wrong foods. Longevity expert David Wolfe shows us some whole foods that not only help heal these disorders, but that taste great in a NutriBlast.From:thenutribulletViews:20 3ratingsTime:06:57More inPeople Blogs

More:
Blasting for Skin Disorders - Video

Psoriasis Treatment: When You Need Clear Skin Fast
Stop the itch immediately - really. Eliminate the symptoms - no joke. Naturally. One of the best psoriasis treatments you #39;ll find, and it #39;s all-natural. Hear testimonials on the website: DermaYantra.com. Derma Yantra is proud to be a leader in relief and treatment of psoriasis.From:DermaYantraViews:0 0ratingsTime:01:52More inHowto Style

Continued here:
Psoriasis Treatment: When You Need Clear Skin Fast - Video

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Idera Pharmaceuticals (IDRA) today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period. None of the 12 placebo-treated patients had improvement in this range; this difference was statistically significant (p<0.005). The Company believes the results of this trial provide clinical proof-of-concept for the mechanism of action of selective TLR inhibition in patients with psoriasis and potentially other autoimmune and inflammatory disorders.

The clinical activity of IMO-3100 demonstrated in patients with moderate-to-severe plaque psoriasis is encouraging, especially given the short duration of treatment in this study that was designed for initial explorations of safety and efficacy, commented Alexa Kimball, M.D., M.P.H., Vice Chair, Department of Dermatology at Massachusetts General Hospital, Boston, and an investigator in the trial.

The achievement of statistically significant PASI reductions with only four weeks of treatment in a placebo-controlled double-blind trial directly supports the rationale that the modulation of specific TLRs plays a key role in the treatment of psoriasis and, potentially, other autoimmune and inflammatory disorders, commented James Krueger, M.D., Ph.D., of The Rockefeller University, New York. We are excited to see these data, which demonstrate the translation of targeting a novel mechanism of action into clinical activity and support further studies of TLR antagonists for the treatment of psoriasis. Our laboratory is continuing to evaluate the immunological pathways by which TLR antagonists suppress the signaling cascades that underlie psoriasis and have the potential to open up a new approach to disease treatment.

About the IMO-3100 Phase 2 Trial in Psoriasis

The Phase 2 trial was a randomized, double-blind, placebo-controlled trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. In the trial, 44 patients were randomized to receive IMO-3100 monotherapy at 0.16 or 0.32 mg/kg or placebo by subcutaneous injection once weekly for four weeks with four weeks of follow-up. Assessments of safety were performed throughout the treatment and follow-up periods. Multiple parameters were monitored to assess the clinical activity of IMO-3100, including Psoriasis Area Severity Index (PASI), mean focal psoriasis severity and Physician Global Assessment (PGA) scores. In addition to the clinical assessments, biopsies of psoriasis plaques were evaluated for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action. Patients were enrolled at eleven sites in the United States.

Top-line clinical results from this trial include:

Skin biopsies were collected at baseline and after completion of treatment to investigate changes in epidermal thickness and immune cell infiltrates. Change in epidermal thickness was the primary endpoint for the trial. Placebo treated patients had a median change in epidermal thickness of +7.7% compared to a median change of -6.4% among IMO-3100 treated patients; this difference was not statistically significant. A known limitation of skin biopsies after four weeks of treatment is that psoriatic plaques do not resolve in a uniform fashion, and therefore, biopsies may not provide a representative sampling of lesions (ref: Ann Rheum Dis 2005;64:65-68).

The Company plans to present complete clinical data from this trial at an upcoming medical meeting.

We believe this trial in patients with moderate-to-severe plaque psoriasis provides clinical proof-of-concept for this first-in-class TLR antagonist, which represents a novel approach to the treatment of autoimmune diseases. We are very pleased to have observed clinical responses after only four weeks of treatment, stated Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera. The insights gained from this trial support expansion of our TLR antagonist program for the treatment of autoimmune diseases. In 2013, we plan to advance the clinical development of a selective TLR antagonist for the treatment of moderate-to-severe plaque psoriasis and also for the treatment of lupus.

View original post here:
Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to ...

6 x 120g Pots
Acheter sur le siite FR d #39;Amazon http://www.amazon.fr Descriptions du produit 6 x 120g Pots Our geranium and rose shea butter body butter is ideal as a deep hydrating body moisturiser, with a wonderfully feminine aphrodisiac scent and feel. No parabens, vegan, no added colour, 100% natural, with fair-trade shea butter. This SheaByNature intensive shea body butter is ideal for people with very dry skin, sensitive skin or ezcema, psoriasis, dermatitis prone skin. We have specially blended this body butter with some of Africa #39;s finest and most nutritious oils. This body butter contains 50 % unrefined shea shea butter so that you can benefit from both the healing and the moisturising qualities of this amazing oil. It has been fragranced with the seductive, floral, essential oils of Geranium and Rose. Unrefined shea Butter deeply moisturises, heals, protects and rejuvenates. Cocoa butter softens and enriches your skin. Coconut oil smoothes, moisturises and adds a healthy glow to your skin. Sunflower oil helps to improve the elasticity and suppleness of your skin. Our shea body butter will make an amazing difference to your skin. The romantic floral scent will make you fall in love.KEY INGREDIENTS: organic shea butter, cocoa butter, coconut oil, sunflower oil, vitamin E, essential oils of Rose and Geranium, cornstarchCase of 6 x 120g pots is ideal for gifts, party packs, starting a small business... Divulgation: ParanoShop participe au Programme Partenaires d #39;Amazon EU, un programme d ...From:Korey WallingViews:0 0ratingsTime:00:58More inHowto Style

See the original post:
6 x 120g Pots - Video

Psoriasis Free For Life Review - Natural Psoriasis Remedies
From:Sabine RadViews:0 0ratingsTime:03:39More inFilm Animation

Read more:
Psoriasis Free For Life Review - Natural Psoriasis Remedies - Video